Survival and Quality of Life of Patients with Advanced Pancreatic Cancer ED Hager, H Dziambor, D Hohmann, BioMed-Hospitals, Bad Bergzabern, Germany Objective: Reproducible responses to single-agent or combination chemotherapy are <10% and the percentage of symptomatic relief by treatment with 5-FU or gemcitabine is 5% and 25%, respectively, with a MST of 4-6 months (1). Chemotherapy plus irradiation increases survival time not appreciably (2-4 months), but is accompanies with heavy side effects. In a retrospective study, a prolongation of median surval time (MST) of patients (pts) with pancreatice cancer of 12 months was observed by a multimodal treatment without chemotherapy. (2,3) Therefore in a prospective trial the results of the retrospective study should be tested and the quality of life (QOL) estimated. Methods: In a prospective study 46 pts with far advanced, nonresectable, recurrent or metastasized adenocarinoma of the pancreas were treated. Median age of study entry was 62 years (range 38-82). In the median Karnofsky Index 50% (range 30-90). Six patients suffered from jaundice and 10 showed ascites at study entry. The multimodal non-toxic treatment consisted of high-dose enzyme therapy, hormonal therapies(Tamoxifen, GnRH analogues), differentiating agents, unspecific immunotherapies (thymus peptides, mistletoe-lectins), and regional deep hyperthermia. (13.56 MHz, Therathem, Italy). The QOL was measured by the EORTC QLQ-C30; analysis has been performedfor 3 treatment cycles. Summary and Conclusion: 1. MST of pts with far advanced carcinoma of the pancreas was prolonged compared to CTx alone if treated with a multimodal non-toxic Tx. 2. 1-yr OSR of 41% and 5-year OSR of 9% was clinically significantly increased compared to 3-18% and <0.2% with chemotherapy. 3. Quality of Life and appetite was improved statistical significantly at each treatment cycle and pain reduced. 4. The treatment is safe and well-tolerated. 5. The prospective open-label study confirms results of a previous retrospective trial. 6. Symptom relief could be achieved after rechallenge following discontinuation of Tx. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.